KRAS and neoplasm: STAT3 sustains the KRAS-dependent phenotype and tumor aggressiveness, with the potential for improved efficacy of anti-RAS drugs, whereas SMAD4 promotes KRAS independence at the expense of enhanced therapy resistance.